Prelude Therapeutics To Engage In Hematology And Oncology Summit

Prelude Therapeutics Incorporated is a clinical-stage company specialising in precision oncology. It announced its participation in the upcoming Citizens JMP Securities Hematology and Oncology Summit today. The virtual event is scheduled for December 2, 2024. 

On Monday, December 2, at 11:30 a.m. ET, Prelude’s Chief Executive Officer, Kris Vaddi, Ph.D., and President and Chief Medical Officer, Jane Huang, M.D., will participate in a fireside chat.

The live webcast of the discussion will be accessible through the Events and Presentations section of the company’s website. For convenience, a session recording will be archived and available for viewing on the site for 90 days.